David E. Gilham Manchester Cancer Research Centre Building, Department Cancer Sciences University of Manchester Biography Publications Institution JoVE Articles David E. Gilham has not added a biography. If you are David E. Gilham and would like to personalize this page please email our Author Liaison for assistance. Publications Ex Vivo Expanded Tumour-infiltrating Lymphocytes from Ovarian Cancer Patients Release Anti-tumour Cytokines in Response to Autologous Primary Ovarian Cancer Cells Cancer Immunology, Immunotherapy : CII. Oct, 2018 | Pubmed ID: 30039427 Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer Journal of Immunotherapy (Hagerstown, Md. : 1997). Apr, 2018 | Pubmed ID: 29239915 The Clinical Efficacy of First-generation Carcinoembryonic Antigen (CEACAM5)-specific CAR T Cells is Limited by Poor Persistence and Transient Pre-conditioning-dependent Respiratory Toxicity Cancer Immunology, Immunotherapy : CII. Nov, 2017 | Pubmed ID: 28660319 Differential Role of Th1 and Th2 Cytokines in Autotoxicity Driven by CD19-specific Second-generation Chimeric Antigen Receptor T Cells in a Mouse Model Journal of Immunology (Baltimore, Md. : 1950). Apr, 2014 | Pubmed ID: 24623129 CAR T Cells: Driving the Road from the Laboratory to the Clinic Immunological Reviews. Jan, 2014 | Pubmed ID: 24329792 Isolation of Tumor Antigen-specific Single-chain Variable Fragments Using a Chimeric Antigen Receptor Bicistronic Retroviral Vector in a Mammalian Screening Protocol Human Gene Therapy Methods. Dec, 2013 | Pubmed ID: 24028672 Targeting T Cells to Tumor: Exploiting the Chimeric Antibody Receptor Immunotherapy. Sep, 2013 | Pubmed ID: 23998728 Potential Limitations of the NSG Humanized Mouse As a Model System to Optimize Engineered Human T Cell Therapy for Cancer Human Gene Therapy Methods. Oct, 2013 | Pubmed ID: 23931270 Chimeric Antigen Receptors for T-cell Based Therapy Methods in Molecular Biology (Clifton, N.J.). 2012 | Pubmed ID: 22907378 Targeting Breast Cancer Vaccines to Dendritic Cells: Improved Immunological Responses with Less Protein? Breast Cancer Research : BCR. May, 2012 | Pubmed ID: 22643384 CAR-T Cells and Solid Tumors: Tuning T Cells to Challenge an Inveterate Foe Trends in Molecular Medicine. Jul, 2012 | Pubmed ID: 22613370 Targeted Immunotherapy of Cancer with CAR T Cells: Achievements and Challenges Cancer Immunology, Immunotherapy : CII. Jul, 2012 | Pubmed ID: 22527245 Regulation of Autologous Immunity to the Mouse 5T4 Oncofoetal Antigen: Implications for Immunotherapy Cancer Immunology, Immunotherapy : CII. Jul, 2012 | Pubmed ID: 22127365 Gene Delivery of a Mutant TGFβ3 Reduces Markers of Scar Tissue Formation After Cutaneous Wounding Molecular Therapy : the Journal of the American Society of Gene Therapy. Dec, 2010 | Pubmed ID: 20736928 Functional Expression of Secreted Proteins from a Bicistronic Retroviral Cassette Based on Foot-and-mouth Disease Virus 2A Can Be Position Dependent Human Gene Therapy. Nov, 2010 | Pubmed ID: 20528679 Development of Adoptive Cell Therapy for Cancer: a Clinical Perspective Human Gene Therapy. Jun, 2010 | Pubmed ID: 20408760 Natural Expression of the CD19 Antigen Impacts the Long-term Engraftment but Not Antitumor Activity of CD19-specific Engineered T Cells Journal of Immunology (Baltimore, Md. : 1950). Feb, 2010 | Pubmed ID: 20089697 Development of a Flow Cytometric Co-immunoprecipitation Technique for the Study of Multiple Protein-protein Interactions and Its Application to T-cell Receptor Analysis Cytometry. Part A : the Journal of the International Society for Analytical Cytology. Apr, 2010 | Pubmed ID: 20033991 Cytokine Stimulation and the Choice of Promoter Are Critical Factors for the Efficient Transduction of Mouse T Cells with HIV-1 Vectors The Journal of Gene Medicine. Feb, 2010 | Pubmed ID: 20033928 The Second Cellular Therapy of Cancer Symposium, 27-29 March 2009, Milan, Italy Cancer Immunology, Immunotherapy : CII. Jun, 2010 | Pubmed ID: 19669146 The Combination of Cyclophosphamide and Human T Cells Genetically Engineered to Target CD19 Can Eradicate Established B-cell Lymphoma British Journal of Haematology. Jul, 2008 | Pubmed ID: 18477047 O6-Methylguanine-DNA Methyltransferase Inactivation and Chemotherapy British Medical Bulletin. 2008 | Pubmed ID: 18245773 Adoptive Transfer of T(reg) Depleted Autologous T Cells in Advanced Renal Cell Carcinoma Cancer Immunology, Immunotherapy : CII. May, 2008 | Pubmed ID: 17899077 Eotaxin-2 and Colorectal Cancer: a Potential Target for Immune Therapy Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Oct, 2007 | Pubmed ID: 17908961 Cellular Therapy of Cancer Symposium December 2nd-3rd 2006 Manchester, UK Cancer Immunology, Immunotherapy : CII. Jun, 2007 | Pubmed ID: 17333180 Combination of Vaccination and Chimeric Receptor Expressing T Cells Provides Improved Active Therapy of Tumors Journal of Immunology (Baltimore, Md. : 1950). Oct, 2006 | Pubmed ID: 16982863 Killing of Non-Hodgkin Lymphoma Cells by Autologous CD19 Engineered T Cells British Journal of Haematology. May, 2005 | Pubmed ID: 15842655 The Role of Extracellular Spacer Regions in the Optimal Design of Chimeric Immune Receptors: Evaluation of Four Different ScFvs and Antigens Journal of Immunotherapy (Hagerstown, Md. : 1997). May-Jun, 2005 | Pubmed ID: 15838376 Gene Therapy of Patient-derived T Lymphocytes to Target and Eradicate Colorectal Hepatic Metastases Diseases of the Colon and Rectum. Jun, 2003 | Pubmed ID: 12794582 Primary Polyclonal Human T Lymphocytes Targeted to Carcino-embryonic Antigens and Neural Cell Adhesion Molecule Tumor Antigens by CD3zeta-based Chimeric Immune Receptors Journal of Immunotherapy (Hagerstown, Md. : 1997). Mar-Apr, 2002 | Pubmed ID: 12074044 Syngena mus B-cells lymfom modell för preklinisk utvärdering av CD19 CAR T-celler Gray Kueberuwa1, Weiming Zheng1, Milena Kalaitsidou1, David E. Gilham1,2, Robert E. Hawkins1 1Manchester Cancer Research Centre Building, Department Cancer Sciences, University of Manchester, 2Celyad JoVE 58492 Cancer Research
Syngena mus B-cells lymfom modell för preklinisk utvärdering av CD19 CAR T-celler Gray Kueberuwa1, Weiming Zheng1, Milena Kalaitsidou1, David E. Gilham1,2, Robert E. Hawkins1 1Manchester Cancer Research Centre Building, Department Cancer Sciences, University of Manchester, 2Celyad JoVE 58492 Cancer Research